← Back to Clinical Trials
Recruiting NCT06137339

NCT06137339 AvoCog - the Effect of Daily Avocado Intake on Cognitive Function in Older Adults

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06137339
Status Recruiting
Phase
Sponsor University of Kansas Medical Center
Condition Brain Aging
Study Type INTERVENTIONAL
Enrollment 70 participants
Start Date 2024-04-09
Primary Completion 2025-12

Eligibility & Interventions

Sex All sexes
Min Age 65 Years
Max Age 85 Years
Study Type INTERVENTIONAL
Interventions
Avocado Group

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 70 participants in total. It began in 2024-04-09 with a primary completion date of 2025-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to determine if adding avocados to the diet of impacts cognition in 70 older adults, age 65-85, without dementia. We will test for change in functional MRI, cognitive performance, and brain blood flow. Intervention group participants will be asked to consume 1 avocado per day for 12 weeks. Participants in the control group will be asked to continue their normal intake for 12 weeks. Throughout the study, participants will be asked to perform cognitive tests, MRI, blood tests, and questionnaires.

Eligibility Criteria

Inclusion Criteria: * Males and females aged 65-85 years * Good general health with no concomitant disease * BMI 18.5 - 35 kg/m2 * Mini Mental State Exam ≥26 * Reports consuming ≤2 medium avocados per month * Reports consuming ≤3 servings of carotenoid-rich foods per week and ≤3 servings of fruits and vegetables per day * Skin carotenoid content \<400 Exclusion Criteria: * Unwilling or unable to consume avocado * Latex allergy * Consistently taking lutein + zeaxanthin supplements * Skin carotenoid content ≥400 * Central neurological disease such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, stroke, brain tumor, etc. * Serious medical risk: cancer requiring chemotherapy or radiation within the past 5 years, recent cardiac event (i.e. heart attack, etc.) * Diabetes mellitus or uncontrolled hypertension * Use of psychoactive or investigational medications * Consumption of ≥3 alcoholic drinks per day or substance abuse * Unable to undergo MRI

Contact & Investigator

Central Contact

Emma Kelly, MS

✉ ekelly9@kumc.edu

📞 913-588-7683

Frequently Asked Questions

Who can join the NCT06137339 clinical trial?

This trial is open to participants of all sexes, aged 65 Years or older, up to 85 Years, studying Brain Aging. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06137339 currently recruiting?

Yes, NCT06137339 is actively recruiting participants. Contact the research team at ekelly9@kumc.edu for enrollment information.

Where is the NCT06137339 trial being conducted?

This trial is being conducted at Kansas City, United States.

Who is sponsoring the NCT06137339 clinical trial?

NCT06137339 is sponsored by University of Kansas Medical Center. The trial plans to enroll 70 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology